Chromadex (NASDAQ: CDXC) and OvaScience (NASDAQ:OVAS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings.
Institutional and Insider Ownership
6.1% of Chromadex shares are held by institutional investors. Comparatively, 55.1% of OvaScience shares are held by institutional investors. 11.6% of Chromadex shares are held by insiders. Comparatively, 9.5% of OvaScience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This table compares Chromadex and OvaScience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Chromadex and OvaScience’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Chromadex||$26.81 million||11.41||-$2.92 million||($0.23)||-24.70|
Chromadex has higher revenue and earnings than OvaScience. Chromadex is trading at a lower price-to-earnings ratio than OvaScience, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Chromadex has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, OvaScience has a beta of 3.73, meaning that its stock price is 273% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Chromadex and OvaScience, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chromadex presently has a consensus price target of $7.50, suggesting a potential upside of 32.04%. OvaScience has a consensus price target of $8.00, suggesting a potential upside of 620.72%. Given OvaScience’s higher probable upside, analysts clearly believe OvaScience is more favorable than Chromadex.
Chromadex beats OvaScience on 9 of the 14 factors compared between the two stocks.
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
OvaScience, Inc. is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue. The Company’s AUGMENT treatment is designed to improve egg health by supplementing a mitochondrial deficiency. With the AUGMENT treatment, energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the in vitro fertilization process to supplement the existing mitochondria. Its OvaPrime treatment is a fertility treatment designed to replenish a woman’s ovary by increasing her egg reserve using her own EggPC cells. Its OvaTure treatment is a fertility treatment that seeks to create mature fertilizable eggs in vitro from a woman’s own EggPC cells without the need for hormone hyperstimulation.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.